Gene Therapy for Neurodegenerative Diseases
Patent Information
- Application Number
- JP2023532127
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-25
- Filing Date
- 2021-11-24
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for Alzheimer's disease (AD) do not effectively address the progressive neuronal damage caused by amyloid-β plaques and tau tangles, particularly in late-onset and autosomal dominant forms, and there is a need for targeted gene therapies to mitigate the risk and onset of cognitive impairment.
The use of expression constructs encoding APOE Christchurch proteins, such as APOE3ch and APOE2ch, combined with inhibitory RNAs to target and inhibit APOE4 expression, delivered via recombinant adeno-associated virus (rAAV) vectors, to modulate neuronal function and reduce tau pathology.
Delivering APOE Christchurch proteins and inhibitory RNAs via rAAV vectors delays the onset of mild cognitive impairment and reduces tau pathology in AD patients, particularly those with PSEN1 E280A mutations, providing a neuroprotective effect.
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims the benefit under 35 U.S.C. 119(e) of the filing date of U.S. Provisional Application No. 63 / 118,060, entitled "GENE THERAPIES FOR NEURODEGENERATIVE DISEASE," filed November 25, 2020, the entire contents of each of which are incorporated herein by reference.
[0002] Sequence Listing This application contains a Sequence Listing that was submitted in ASCII format via FES-Web and is incorporated herein by reference in its entirety. The ASCII copy was created on November 24, 2021, is named P109470016WO00-SEQ-LJG, and is 24,073 bytes in size. [Background technology]
[0003] background Alzheimer's disease (AD) is the most common form of dementia, affecting more than 5 million people in the United States alone. Alzheimer's disease is an irreversible, progressive brain disorder characterized by the presence of abnormal protein deposits throughout the brain, which inhibit neuronal function, destroy connections between neurons, and ultimately lead to cell death. These deposits include amyloid-β plaques and tangles formed by phosphorylated tau protein. Patients with mild AD experience memory loss, leading to wandering, difficulty handling money, repetitive questioning, and personality and behavioral changes. Patients with moderate AD exhibit increased memory loss, become confused and have difficulty recognizing friends and family, become unable to learn new things, and experience hallucinations, delusions, and paranoia. Patients with severe AD are unable to communicate and become completely dependent on others for their care. Eventually, protein plaques and tangles spread throughout the brain, leading to significant tissue atrophy. Summary of the Invention
[0004] overview Most Alzheimer's disease (AD) patients have late-onset AD, with symptoms appearing in subjects in their mid-60s. The apolipoprotein E (APOE) gene is involved in the development of late-onset AD. APOE has several isoforms, including APOE2, which is protective against AD, and APOE4, which is associated with an increased risk of developing late-onset AD. Homozygous patients who carry two copies of APOE4 (e.g., APOE4 + / + Patients with a genomic DNA sequence (e.g., APOE4, APOE2, APOE3, APOE4-positive or -negative gene) are at greater risk of developing late-onset AD compared with heterozygous patients carrying one copy of APOE4 and one copy of either APOE2 or APOE3. In addition, presenilin 1 (PSEN1) mutations (e.g., PSEN1 E280A mutation) are associated with autosomal dominant AD. It has been found that PSEN1 E280A mutation carriers who are homozygous for the APOE3 Christchurch mutation (e.g., APOE3 R136S mutation) develop cognitive impairment much later than PSEN1 E280A mutation carriers who are not homozygous for the APOE3 Christchurch mutation (e.g., APOE3 R136S mutation).
[0005] Aspects of the present disclosure relate to compositions and methods for treating subjects with or suspected of having AD (e.g., ADAD). The disclosure is based, in part, on an expression construct encoding an APOE Christchurch protein (e.g., APOE3ch protein and / or APOE2ch protein). In some aspects, the expression construct also encodes an inhibitory RNA (e.g., shRNA, miRNA, amiRNA, etc.) that targets an AD-related gene (e.g., APOE, such as APOE4, APOE3, and / or APOE2).
[0006] In some aspects, the disclosure provides isolated nucleic acids, including expression constructs, that include a nucleic acid sequence encoding an APOE Christchurch protein. In some embodiments, the APOE Christchurch protein is an APOE2 Christchurch protein. In some embodiments, the APOE2 Christchurch protein comprises an amino acid sequence at least 80% identical to SEQ ID NO:8. In some embodiments, an expression construct encoding the APOE2 Christchurch protein comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:9. In some embodiments, the APOE Christchurch protein is an APOE3 Christchurch protein. In some embodiments, the APOE3 Christchurch protein comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:6. In some embodiments, an expression construct encoding the APOE3 Christchurch protein comprises a nucleic acid sequence at least 80% identical to SEQ ID NO:7.
[0007] In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of one or more APOE gene isoforms (e.g., APOE4, APOE3, APOE2, etc.). In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE4. In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE2. In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE3. In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE4 and APOE2. In some embodiments, the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE4, APOE3, and APOE2. In some embodiments, the inhibitory nucleic acid is encoded by a sequence set forth in any one of SEQ ID NOs: 12-23.
[0008] In some embodiments, the expression construct further comprises a first promoter operably linked to a nucleic acid sequence encoding an APOE Christchurch protein. In some embodiments, the first promoter is operably linked to a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of one or more APOE isoforms (e.g., APOE4, APOE3, APOE2, etc.). In some embodiments, the expression construct further comprises a second promoter operably linked to a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of one or more APOE isoforms (e.g., APOE4, APOE3, APOE2, etc.). In some embodiments, the first promoter and / or the second promoter are independently a chicken beta actin (CBA) promoter, a CAG promoter, a CD68 promoter, or a JeT promoter. In some embodiments, the expression construct is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs). In some embodiments, the ITRs are AAV2 ITRs.
[0009] In some embodiments, the isolated nucleic acid comprises a sequence represented by any one of SEQ ID NOs: 6-11. In some aspects, the present disclosure provides a vector comprising the isolated nucleic acid described herein. In some embodiments, the vector is a plasmid. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a recombinant AAV (rAAV) vector or a baculovirus vector.
[0010] In some aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) comprising: (i) AAV capsid proteins; and (ii) an isolated nucleic acid or vector as described herein. In some embodiments, the AAV capsid protein can cross the blood-brain barrier. In some embodiments, the AAV capsid protein is an AAV9 capsid protein or an AAVrh.10 capsid protein. In some embodiments, the rAAV transduces neural and non-neuronal cells in the central nervous system (CNS).
[0011] In some aspects, the disclosure provides a host cell comprising an isolated nucleic acid, vector, or rAAV as described herein. In some aspects, the disclosure provides a composition comprising an isolated nucleic acid, vector, or rAAV as described herein. In some embodiments, the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
[0012] In some aspects, the present disclosure provides methods comprising administering to a subject having or suspected of having Alzheimer's disease an isolated nucleic acid, vector, rAAV, or composition as described herein. In some embodiments, the administration comprises direct injection into the CNS of the subject. In some embodiments, the direct injection comprises intracerebral injection, intraparenchymal injection, intrathecal injection, or any combination thereof. In some embodiments, the direct injection into the CNS of the subject comprises convection-enhanced delivery (CED). In some embodiments, the administration comprises peripheral injection. In some embodiments, the peripheral injection comprises intravenous injection.
[0013] In some embodiments, the subject has or is suspected of having autosomal dominant Alzheimer's disease (ADAD). In some embodiments, the subject has at least one mutation in the PSEN1 gene. In some embodiments, the mutation in the PSEN1 gene causes an E280A mutation in the presenilin 1 protein. In some embodiments, the subject is not homozygous for the APOE3 Christchurch mutation, wherein the APOE3 Christchurch mutation causes an R136S mutation in the APOE3 protein. In some embodiments, the administration results in a delayed onset of mild cognitive impairment (MIC) compared to subjects who do not receive the administration. [Brief explanation of the drawings]
[0014] Brief description of the drawings [Figure 1] FIG. 1 shows a schematic diagram depicting one embodiment of a vector encoding an APOE Christchurch variant protein. [Figure 2-1] Figure 2 shows a multiple sequence alignment of wild-type APOE2, APOE2_Christchurch, and APOE3_Christchurch. SEQ ID NOs: 3, 8, and 6 are shown from top to bottom. [Figure 2-2]Figure 2 shows a multiple sequence alignment of wild-type APOE2, APOE2_Christchurch, and APOE3_Christchurch. SEQ ID NOs: 3, 8, and 6 are shown from top to bottom. DETAILED DESCRIPTION OF THE INVENTION
[0015] Detailed Description The present disclosure is based in part on compositions and methods for expressing a combination of AD-related gene products in a subject.Gene products can be proteins, protein fragments (for example, parts), interfering nucleic acids that inhibit AD-related genes, etc.In some embodiments, gene products are proteins or protein fragments that are encoded by AD-related genes.In some embodiments, gene products are inhibitory nucleic acids (for example, shRNA, siRNA, miRNA, amiRNA, etc.) that inhibit AD-related genes.
[0016] AD-related genes refer to genes encoding gene products that are genetically, biochemically, or functionally related to Alzheimer's disease (AD). For example, individuals with at least one copy of presenilin 1 (PSEN1) containing E280A mutation are at increased risk of developing autosomal dominant Alzheimer's disease (ADAD). In some embodiments, APOE3 Christchurch mutation homozygotes (APOE3ch + / + ) exhibits neuroprotective effects in AD patients with the presenilin 1 (PSEN1) E280A mutation. In other cases, individuals with at least one copy of APOE4 are at increased risk of developing late-onset AD. In another example, APOE2 exhibits neuroprotective effects in a mouse model of AD. As used herein, the term "neuroprotective" refers to the protection of the structure and / or function of neurons in a cell or subject compared to the protection of the structure and / or function of neurons in a cell or subject in the absence of neuroprotection (e.g., the absence of a neuroprotective agent or protein).
[0017] Isolated nucleic acids and vectors The isolated nucleic acid may be DNA or RNA. In some aspects, the present disclosure provides an isolated nucleic acid comprising an expression construct comprising a nucleic acid sequence encoding an APOE Christchurch protein (e.g., APOE2 Christchurch protein and / or APOE3 Christchurch protein). Aspects of the present disclosure also relate to an isolated nucleic acid comprising an expression construct comprising a nucleic acid sequence encoding an APOE Christchurch protein (e.g., APOE2 Christchurch protein and / or APOE3 Christchurch protein) and a nucleic acid sequence encoding one or more inhibitory nucleic acids (e.g., dsRNA, siRNA, miRNA, amiRNA, etc.) targeting one or more endogenous APOE gene isoforms (e.g., isoforms 2, 3, and / or 4 of the APOE gene).
[0018] APOE protein refers to apolipoprotein E, a lipid-binding protein that plays a role in the catabolism of triglyceride-rich lipoproteins. There are three major isoforms of APOE, designated APOE2, APOE3, and APOE4. Each isoform differs from the others at two positions: amino acid 130 and amino acid 176 (also referred to as positions 112 and 158, respectively, when the protein's signal peptide is excluded). APOE2 contains Cys130 / Cys176 and has been observed to be associated with type III hyperlipidemia and other diseases, but also plays a neuroprotective role. APOE3 contains Cys130 / Arg176 and is the most common APOE allele. APOE4 contains Arg130 / Arg176 and has been observed to be associated with late-onset Alzheimer's disease, atherosclerosis, adverse outcomes in traumatic brain injury (TBI), and other diseases. In humans, the APOE gene is located on chromosome 19. In some embodiments, APOE4 is encoded by the nucleic acid sequence represented by SEQ ID NO: 1. In some embodiments, APOE2 is encoded by the nucleic acid sequence represented by SEQ ID NO: 2. In some embodiments, APOE3 is encoded by the nucleic acid sequence represented by SEQ ID NO: 4.
[0019] In some aspects, the present disclosure provides a method for treating an APOE3 Christchurch mutation (e.g., APOE3ch + / +) plays a neuroprotective role in AD patients (e.g., AD patients who are PSEN1 E280A mutation carriers). As described herein, APOE Christchurch mutation (APOEch) refers to an APOE mutant protein harboring an R136S amino acid substitution associated with a mutation at codon 154 of the APOE coding sequence. In some embodiments, the isolated nucleic acids described herein comprise an expression construct encoding an APOE Christchurch protein. In some embodiments, the nucleic acid sequence encoding the APOE Christchurch protein is codon-optimized. In some embodiments, the isolated nucleic acid encodes an APOE3 Christchurch protein, or a fragment thereof. The term "fragment" refers to a portion of a polypeptide or nucleic acid molecule of a reference polypeptide or nucleic acid molecule (e.g., a wild-type or full-length isoform). In some embodiments, the fragment is a truncation from either end of the reference molecule and has at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the reference molecule (e.g., wild-type or full-length isoform). In some embodiments, the fragment contains amino acid or nucleotide deletions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more deletions) over the length of the reference molecule (e.g., wild-type or full-length isoform). In some embodiments, the isolated nucleic acid encodes a protein having an amino acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:6.In some embodiments, the isolated nucleic acid encodes an APOE2 Christchurch protein or a fragment thereof. In some embodiments, the isolated nucleic acid encodes a protein having an amino acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:8. The protein fragment may comprise about 50%, about 60%, about 70%, about 80%, about 90%, or about 99% of the protein encoded by the APOE2 gene. In some embodiments, the protein fragment comprises between 50% and 99.9% (e.g., any value between 50% and 99.9%) of the protein having the amino acid sequence set forth in SEQ ID NO:6 or 8.
[0020] In some embodiments, the gene product (e.g., a transgene encoding an APOE Christchurch protein) is encoded by a coding portion of a naturally occurring gene (e.g., a cDNA). In some embodiments, the gene product is a protein (or a fragment thereof) encoded by an APOE gene harboring an APOE Christchurch mutation. In some embodiments, the gene product is a protein (or a fragment thereof) encoded by an APOE3 gene (e.g., APOE3ch) harboring an APOE Christchurch mutation. In some embodiments, the APOE3ch gene comprises a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO:7. In some embodiments, the gene product is a protein (or a fragment thereof) encoded by an APOE2 gene (e.g., APOE2ch) harboring an APOE Christchurch mutation. In some embodiments, the APOE3ch gene comprises a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleic acid sequence set forth in SEQ ID NO:9. In some embodiments, the nucleic acid sequence encoding the APOE Christchurch protein is codon-optimized.In some embodiments, the codon-optimized nucleic acid sequence encoding the APOE3ch protein is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleic acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the codon-optimized nucleic acid sequence encoding the APOE2ch protein is at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleic acid sequence as set forth in SEQ ID NO: 11.
[0021] In some embodiments, the isolated nucleic acid as described herein further comprises a nucleic acid sequence encoding one, two, three, four, five, six, seven, eight, nine, ten, or more inhibitory nucleic acids (e.g., dsRNA, siRNA, shRNA, miRNA, amiRNA, etc.). In some embodiments, the isolated nucleic acid encodes more than ten inhibitory nucleic acids. In some embodiments, each of the one or more inhibitory nucleic acids targets a different gene or portion of a gene (e.g., a first miRNA targets a target sequence of a first gene, and a second miRNA targets a target sequence of a second gene that is different from the first target sequence). In some embodiments, each of the one or more inhibitory nucleic acids targets the same target sequence of the same gene (e.g., the isolated nucleic acid encodes multiple copies of the same miRNA).
[0022] In some embodiments, the isolated nucleic acid encodes a gene product that is an inhibitory nucleic acid that targets (e.g., comprises a region that hybridizes to or is complementary to) an AD-related gene (e.g., one or more endogenous APOE gene products, such as one or more APOE4 isoforms, APOE3 isoforms, and / or APOE2 isoforms of the APOE gene).Those skilled in the art will recognize that the order of expression of a first gene product (e.g., APOEch protein) and a second gene product (e.g., an inhibitory RNA that targets the APOE4 isoform of the APOE gene) can generally be reversed (e.g., the inhibitory RNA is the first gene product, and APOE2 is the second gene product).
[0023] Inhibitory nucleic acids targeting APOE gene isoform(s) (e.g., APOE4, APOE3, and / or APOE2) may comprise a region of complementarity (e.g., a region of the inhibitory nucleic acid that hybridizes to a target gene, e.g., a gene encoding APOE4, APOE3, and / or APOE2) that is between 6 and 50 nucleotides in length. In some embodiments, the inhibitory nucleic acid comprises a region of complementarity to APOE that is between about 6 and 30, between about 8 and 20, or between about 10 and 19 nucleotides in length. In some embodiments, the inhibitory nucleic acid is complementary to at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 consecutive nucleotides of the APOE sequence. In some embodiments, the inhibitory nucleic acid that targets the APOE gene is non-allele specific (for example, the inhibitory nucleic acid silences all isoforms of the APOE gene). In some embodiments, the inhibitory nucleic acid targets one or more specific alleles of APOE, such as one or more of APOE2, APOE3, and / or APOE4. In some embodiments, the inhibitory nucleic acid does not target (for example, does not inhibit the expression or activity of) the APOE2ch or APOE3ch isoform.
[0024] In some embodiments, the gene product (e.g., inhibitory RNA) hybridizes to a portion of a target gene (e.g., is complementary to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more consecutive nucleotides of a target gene, e.g., the APOE4 isoform of APOE, such as the sequence set forth in SEQ ID NO: 1). In some embodiments, the gene product (e.g., inhibitory RNA) hybridizes to a portion of a target gene (e.g., is complementary to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more consecutive nucleotides of a target gene, e.g., the APOE2 isoform of APOE, such as the sequence set forth in SEQ ID NO: 2). In some embodiments, the gene product (e.g., an inhibitory RNA) hybridizes to a portion of a target gene (e.g., is complementary to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more consecutive nucleotides of the target gene, e.g., the APOE3 isoform of APOE, such as the sequence set forth in SEQ ID NO:4).
[0025] In some embodiments, the expression construct is monocistronic (e.g., the expression construct encodes a single fusion protein comprising a first gene product and a second gene product), while in some embodiments, the expression construct is polycistronic (e.g., the expression construct encodes two different gene products, e.g., two different proteins or protein fragments).
[0026] A polycistronic expression vector can include one or more (e.g., 1, 2, 3, 4, 5, or more) promoters. Any suitable promoter can be used, such as a constitutive promoter, an inducible promoter, an endogenous promoter, a tissue-specific promoter (e.g., a CNS-specific promoter), etc. In some embodiments, the promoter is a chicken beta-actin promoter (CBA promoter), a CAG promoter (e.g., as described in Alexopoulou et al. (2008) BMC Cell Biol. 9:2; doi: 10.1186 / 1471-2121-9-2), a CD68 promoter, or a JeT promoter (e.g., as described in Tornoee et al. (2002) Gene 297(1-2):21-32). In some embodiments, the promoter is operably linked to a nucleic acid sequence encoding a first gene product, a second gene product, or a first and second gene product. In some embodiments, the expression cassette comprises one or more additional regulatory sequences, including, but not limited to, transcription factor binding sequences, intron splice sites, poly(A) addition sites, enhancer sequences, repressor binding sites, or any combination thereof.
[0027] In some embodiments, the nucleic acid sequence encoding the first gene product and the nucleic acid sequence encoding the second gene product are separated by a nucleic acid sequence encoding an internal ribosome entry site (IRES). Examples of IRES sites are described, for example, in Mokrejs et al. (2006) Nucleic Acids Res. 34 (Database issue): D125-30. In some embodiments, the nucleic acid sequence encoding the first gene product and the nucleic acid sequence encoding the second gene product are separated by a nucleic acid sequence encoding a self-cleaving peptide. Examples of self-cleaving peptides include, but are not limited to, T2A, P2A, E2A, F2A, BmCPV 2A, and BmIFV 2A, and those described in Liu et al. (2017) Sci Rep. 7: 2193. In some embodiments, the self-cleaving peptide is a T2A peptide.
[0028] In some embodiments, disorders such as AD are associated with the expression of at least one copy of APOE4.Therefore, in some embodiments, the isolated nucleic acid described herein comprises an inhibitory nucleic acid that reduces or prevents the expression of APOE4 (for example, APOE).The sequence encoding the inhibitory nucleic acid can be placed in the untranslated region (for example, intron, 5'UTR, 3'UTR, etc.) of expression vector.
[0029] In some embodiments, the inhibitory nucleic acid is placed in an intron of the expression construct, e.g., an intron upstream of the sequence encoding the first gene product. The inhibitory nucleic acid can be double-stranded RNA (dsRNA), shRNA, siRNA, microRNA (miRNA), artificial miRNA (amiRNA), or RNA aptamer. Generally, the inhibitory nucleic acid binds to (e.g., hybridizes with) about 6 to about 30 consecutive nucleotides (e.g., any integer between 6 and 30, inclusive) of a target RNA (e.g., mRNA). In some embodiments, the inhibitory nucleic acid molecule is an miRNA or amiRNA, e.g., an miRNA targeting the APOE4 isoform of APOE (the gene encoding the APOE4 protein). In some embodiments, the inhibitory nucleic acid molecule is an miRNA or amiRNA, e.g., an miRNA targeting the APOE3 isoform of APOE (the gene encoding the APOE3 protein). In some embodiments, the inhibitory nucleic acid molecule is a miRNA or amiRNA, for example, a miRNA that targets the APOE2 isoform of APOE (the gene encoding the APOE2 protein). In some embodiments, the miRNA does not contain any mismatches with the region of APOE mRNA to which it hybridizes (e.g., the miRNA is "perfect"). In some embodiments, the inhibitory nucleic acid is an shRNA (e.g., an shRNA that targets APOE), for example, encoded by any one of SEQ ID NOS: 12-23. In some embodiments, the miRNA contains at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) mismatch with the region of APOE mRNA to which it hybridizes.
[0030] In some embodiments, the inhibitory nucleic acid is artificial microRNA (amiRNA). MicroRNA (miRNA) typically refers to small non-coding RNA found in plants and animals, and functions in the transcriptional and post-translational regulation of gene expression. MiRNA is transcribed by RNA polymerase to form a hairpin loop structure called pri-miRNA; this is then processed by enzymes (Drosha, Pasha, spliceosome, etc.) to form a pre-miRNA hairpin structure, which is then processed by Dicer to form miRNA / miRNA* duplex (* indicates the passenger strand of the miRNA duplex), one strand of which is then incorporated into RNA-induced silencing complex (RISC). In some embodiments, the inhibitory RNA described herein is the miRNA that targets the APOE4 isoform of APOE (the gene that encodes APOE4 protein). In some embodiments, the inhibitory RNA described herein is the miRNA that targets the APOE3 isoform of APOE (the gene that encodes APOE3 protein). In some embodiments, an inhibitory RNA as described herein is an miRNA that targets the APOE2 isoform of APOE (the gene that encodes the APOE2 protein).
[0031] In some embodiments, the inhibitory nucleic acid targeting APOE (e.g., the APOE4, APOE3, or APOE2 isoform of APOE) comprises a miRNA / miRNA* duplex. In some embodiments, the miRNA strand of the miRNA / miRNA* duplex comprises or consists of a sequence encoded by any one of SEQ ID NOs: 12-23. In some embodiments, the miRNA* strand of the miRNA / miRNA* duplex comprises or consists of a sequence encoded by any one of SEQ ID NOs: 12-23.
[0032] Artificial microRNAs (amiRNAs) are derived by modifying natural miRNAs to replace the natural targeting region of the pre-mRNA with a targeting region of interest. For example, a naturally expressed miRNA can be used as a scaffold or framework (e.g., a pri-miRNA scaffold), with the stem sequence replaced with that of an miRNA targeting a gene of interest. Artificial precursor microRNAs (pre-amiRNAs) are typically processed to preferentially produce a single stable small RNA. In some embodiments, the rAAV vectors and rAAVs described herein contain nucleic acids encoding amiRNAs. In some embodiments, the pri-miRNA scaffold of the amiRNA is derived from a pri-miRNA selected from the group consisting of pri-MIR-21, pri-MIR-22, pri-MIR-26a, pri-MIR-30a, pri-MIR-33, pri-MIR-122, pri-MIR-375, pri-MIR-199, pri-MIR-99, pri-MIR-194, pri-MIR-155, and pri-MIR-451. In some embodiments, the amiRNA comprises a nucleic acid sequence that targets APOE (e.g., the APOE4 isoform of APOE) and an eSIBR amiRNA scaffold, as described, for example, in Fowler et al. Nucleic Acids Res. 2016 Mar 18; 44(5): e48.
[0033] In some embodiments, the amiRNA targeting APOE (e.g., the APOE4, APOE3, or APOE2 isoform of APOE) comprises or consists of a sequence encoded by any one of SEQ ID NOs: 15, 19, and 23. The isolated nucleic acids described herein can exist by themselves or as part of a vector. Generally, the vector is a plasmid, cosmid, phagemid, bacterial artificial chromosome (BAC), or viral vector (e.g., adenoviral vector, adeno-associated viral (AAV) vector, retroviral vector, baculoviral vector, etc.). In some embodiments, the vector is a plasmid (e.g., a plasmid containing an isolated nucleic acid described herein). In some embodiments, the vector is a recombinant AAV (rAAV) vector. The rAAV can contain either the "plus strand" or "minus strand" of the rAAV vector. In some embodiments, the rAAV vector is single-stranded (e.g., single-stranded DNA). In some embodiments, the vector is a baculoviral vector (e.g., an Autographa californica nuclear polyhedrosis (AcNPV) vector).
[0034] Typically, an rAAV vector comprises a transgene (e.g., an expression construct comprising one or more of the following: a promoter, an intron, an enhancer sequence, a protein-coding sequence, an inhibitory RNA-coding sequence, a polyA tail sequence, etc.) flanked by two AAV inverted terminal repeat (ITR) sequences. In some embodiments, the transgene of the rAAV vector comprises an isolated nucleic acid described in this disclosure. In some embodiments, each of the two ITR sequences of the rAAV vector is a full-length ITR (e.g., approximately 145 bp in length and including a functional Rep binding site (RBS) and terminal resolution site (trs)). In some embodiments, one of the ITRs of the rAAV vector is truncated (e.g., shortened or not full-length). In some embodiments, the truncated ITR lacks a functional terminal resolution site (trs) and is used for the generation of self-complementary AAV vectors (scAAV vectors). In some embodiments, the truncated ITR is, for example, the ΔITR described in McCarty et al. (2003) Gene Ther. 10(26):2112-8.
[0035] Aspects of the present disclosure relate to isolated nucleic acids (e.g., rAAV vectors) comprising ITRs with one or more modifications (e.g., nucleic acid additions, deletions, substitutions, etc.) compared to wild-type AAV ITRs, e.g., compared to the wild-type AAV2 ITR (e.g., SEQ ID NO: 24). Wild-type ITRs generally comprise a 125-nucleotide region that self-anneals to form a palindromic, double-stranded T-shaped hairpin structure consisting of two crossarms (formed by sequences designated B / B' and C / C', respectively), a longer stem region (formed by sequences A / A'), and a single-stranded terminal region designated the "D" region. The "D" region of the ITR is generally positioned between the stem region formed by the A / A' sequences and a transgene-containing insert in the rAAV vector (e.g., positioned "inside" the ITR relative to the end of the ITR or proximal to the transgene insert or expression construct in the rAAV vector). The "D" region has been observed to play an important role in encapsidation of rAAV vectors by capsid proteins, as disclosed, for example, in Ling et al. (2015) J Mol Genet Med 9(3).
[0036] An isolated nucleic acid or rAAV vector described herein can further comprise a "TRY" sequence, e.g., as described in Francois, et al. 2005. J Virol The Cellular TATA Binding Protein Is Required for Rep-Dependent Replication of a Minimal Adeno-Associated Virus Type 2 p5 Element. In some embodiments, the TRY sequence is positioned between the ITR (e.g., 5' ITR) of the isolated nucleic acid or rAAV vector and the expression construct (e.g., an insert encoding a transgene).
[0037] In some aspects, the present disclosure relates to a baculovirus vector comprising the isolated nucleic acid or rAAV vector described herein. In some embodiments, the baculovirus vector is an Autographa californica nuclear polyhedrosis (AcNPV) vector, for example, as described in Urabe et al. (2002) Hum Gene Ther 13(16):1935-43 and Smith et al. (2009) Mol Ther 17(11):1888-1896.
[0038] In some aspects, the present disclosure provides a host cell comprising an isolated nucleic acid or vector described herein. The host cell can be a prokaryotic cell or a eukaryotic cell. For example, the host cell can be a mammalian cell, a bacterial cell, a yeast cell, an insect cell, etc. In some embodiments, the host cell is a mammalian cell, such as a HEK293T cell. In some embodiments, the host cell is a bacterial cell, such as an E. coli cell.
[0039] rAAV In some aspects, the present disclosure relates to a recombinant AAV (rAAV) comprising a transgene encoding a nucleic acid described herein (e.g., an rAAV vector described herein). The term "rAAV" generally refers to a viral particle comprising an rAAV vector encapsidated by one or more AAV capsid proteins. The rAAV described in this disclosure may comprise a capsid protein having a serotype selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAV10. In some embodiments, the rAAV comprises a capsid protein derived from a non-human host, e.g., a rhesus AAV capsid protein such as AAVrh.10 or AAVrh.39. In some embodiments, the rAAV described in this disclosure comprises a capsid protein that is a variant of a wild-type capsid protein, e.g., a capsid protein variant that includes at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 (e.g., 15, 20, 25, 50, 100, etc.) amino acid substitutions (e.g., mutations) relative to the wild-type AAV capsid protein from which it is derived.
[0040] In some embodiments, the rAAV described in the present disclosure spreads easily throughout the CNS, especially when introduced into the CSF space or directly into the brain parenchyma.Thus, in some embodiments, the rAAV described in the present disclosure comprises a capsid protein that can cross the blood-brain barrier (BBB).For example, in some embodiments, the rAAV comprises a capsid protein with AAV9 or AAVrh.10 serotype.The production of rAAV is described, for example, in Samulski et al.(1989) J Virol.63(9):3822-8 and Wright(2009) Hum Gene Ther.20(7):698-706.
[0041] In some embodiments, the rAAV described herein (e.g., comprising a recombinant rAAV genome encapsidated by AAV capsid proteins to form rAAV capsid particles) is produced in a baculovirus vector expression system (BEVS). The production of rAAV using BEVS is described, for example, in Urabe et al. (2002) Hum Gene Ther 13(16):1935-43, Smith et al. (2009) Mol Ther 17(11):1888-1896, U.S. Patent No. 8,945,918, U.S. Patent No. 9,879,282, and International PCT Publication WO 2017 / 184879. However, rAAV can be produced using any suitable method (e.g., using recombinant rep and cap genes).
[0042] Pharmaceutical Composition In some aspects, the present disclosure provides a pharmaceutical composition comprising an isolated nucleic acid or rAAV described herein and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not neutralize the biological activity or properties of the compound and is relatively non-toxic, e.g., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0043] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, that is associated with carrying or transporting a compound useful within the present invention into or to a patient so that it can perform its intended function. Additional ingredients that may be included in pharmaceutical compositions used in the practice of the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
[0044] The compositions (e.g., pharmaceutical compositions) provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, intradermal, rectal, vaginal, intraperitoneal, topical (by powder, ointment, cream, and / or drops), mucosal, nasal, buccal, sublingual; intratracheal instillation, bronchial instillation, and / or inhalation; and / or oral spray, nasal spray, and / or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), local administration via the blood and / or lymphatic supply, and / or direct administration to the affected site. Generally, the most appropriate administration route will depend on various factors, such as the properties of the agent (e.g., its stability in the gastrointestinal environment) and / or the condition of the subject (e.g., whether the subject can tolerate oral administration). In certain embodiments, the compounds or pharmaceutical compositions described herein are suitable for topical administration to the eye of a subject.
[0045] method The present disclosure is based in part on a composition for expressing a combination of AD-related gene products in a subject, which act together (e.g., synergistically) to treat Alzheimer's disease.As used herein, "treat" or "treating" refers to (a) preventing or delaying the onset of Alzheimer's disease; (b) reducing the severity of Alzheimer's disease; (c) reducing or preventing the onset of symptoms characteristic of Alzheimer's disease; (d) and / or preventing the worsening of symptoms characteristic of Alzheimer's disease.Alzheimer's disease symptoms include, for example, cognitive dysfunction (e.g., dementia, hallucinations, memory loss, etc.), motor dysfunction (e.g., difficulty performing daily tasks, etc.), and emotional and behavioral dysfunction.
[0046] Accordingly, in some aspects, the present disclosure provides methods comprising administering a composition as described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) to a subject having or suspected of having Alzheimer's disease (e.g., ADAD). As used herein, the term "administering" or "administration" means providing a composition (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) to a subject in a manner that is physiologically and / or pharmacologically useful (e.g., treating a condition such as AD in the subject). In some aspects, the present disclosure provides methods for treating a subject having or suspected of having Alzheimer's disease (e.g., ADAD), comprising administering to the subject a composition as described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV).
[0047] In some embodiments, administration of a composition as described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) results in delayed onset of mild cognitive impairment (MIC), which is the early stage of memory loss or loss of other cognitive abilities (such as language or visual / spatial perception) in subjects (e.g., AD patients) who maintain the ability to independently perform most activities of daily living. In some embodiments, administration of a composition as described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) results in a delay in the onset of mild cognitive impairment (MIC) by more than 1 month, more than 2 months, more than 3 months, more than 4 months, more than 5 months, more than 6 months, more than 7 months, more than 8 months, more than 9 months, more than 10 months, more than 11 months, more than 12 months, more than 1 year, more than 2 years, more than 3 years, more than 4 years, more than 5 years, more than 6 years, more than 7 years, more than 8 years, more than 9 years, or more than 10 years, compared to a subject who is not administered a composition described herein. In some embodiments, administration of a composition as described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) results in a delay in the onset of mild cognitive impairment (MIC) by between 1 month and 3 months, between 1 month and 6 months, between 3 months and 6 months, between 3 months and 9 months, between 6 months and 9 months, between 1 month and 12 months, between 6 months and 12 months, between 1 year and 2 years, between 1 year and 3 years, between 1 year and 4 years, between 1 year and 5 years, between 1 year and 6 years, between 1 year and 7 years, between 1 year and 8 years, between 1 year and 9 years, between 1 year and 10 years, between 10 years and 20 years, or more, compared to a subject who is not administered a composition described herein.
[0048] The subject is typically a mammal, e.g., a human, dog, cat, pig, hamster, rat, mouse, etc. In some embodiments, the subject is a human. In some embodiments, the subject is characterized by a presenilin 1 (PSEN1) E280A mutation allele. The subject is homozygous (e.g., PSEN1 E280A + / +) or heterozygous (e.g., PSEN1 E280A + / + In some embodiments, the subject with the presenilin 1 (PSEN1) E280A mutation is not homozygous for the APOE3 Christchurch mutation (e.g., APOE3 R136S + / - or APOE3 R136S - / - ). In some embodiments, the subject is characterized by an APOE4 allele. The subject is homozygous for APOE4 (e.g., APOE4 + / + ) or heterozygous (e.g., APOE4 + / - In some embodiments, the subject is heterozygous for APOE4 and the subject's second APOE allele is selected from APOE2 and APOE3.
[0049] In some embodiments, the composition is administered directly to the CNS of a subject, for example, by direct injection into the brain and / or spinal cord of the subject. Examples of direct CNS administration methods include, but are not limited to, intracerebral injection, intraventricular injection, intracisternal injection, intraparenchymal injection, intrathecal injection, and any combination thereof. In some embodiments, direct injection into the CNS of a subject results in transgene expression (e.g., expression of the first gene product, the second gene product, and, if applicable, the third gene product) in the midbrain, striatum, and / or cerebral cortex of the subject. In some embodiments, direct injection into the CNS results in transgene expression (e.g., expression of the first gene product, the second gene product, and, if applicable, the third gene product) in the spinal cord and / or CSF of the subject.
[0050] In some embodiments, direct injection into the CNS of a subject comprises convection-enhanced delivery (CED).Convection-enhanced delivery is a therapeutic strategy that involves surgical exposure of the brain and placing a small-diameter catheter directly into the target area of the brain, followed by direct injection of a therapeutic agent (for example, the composition described herein or rAAV) into the subject's brain.CED is described, for example, in Debinski et al.(2009) Expert Rev Neurother.9(10):1519-27. In some embodiments, the composition is administered to the subject's periphery, for example, by peripheral injection. Examples of peripheral injection include subcutaneous injection, intravenous injection, intraarterial injection, intraperitoneal injection, or any combination thereof. In some embodiments, the peripheral injection is intraarterial injection, for example, injection into the subject's carotid artery.
[0051] In some embodiments, a composition described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) is administered both peripherally and directly to the CNS of a subject. For example, in some embodiments, a subject is administered the composition by intra-arterial injection (e.g., injection into the carotid artery) and intraparenchymal injection (e.g., intraparenchymal injection by CED). In some embodiments, the direct injection into the CNS and the peripheral injection are simultaneous (e.g., occur simultaneously). In some embodiments, the direct injection is administered before (e.g., between 1 minute and 1 week, or more before) the peripheral injection. In some embodiments, the direct injection is administered after (e.g., between 1 minute and 1 week, or more after) the peripheral injection.
[0052] The amount of a composition described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) administered to a subject will vary depending on the method of administration. For example, in some embodiments, the rAAV described herein is administered to a subject in an amount of about 10 9 genome copies (GC) / kg and approximately 10 14 Between GC / kg (e.g., about 10 9 GC / kg, approx. 10 10 GC / kg, approx. 10 11 GC / kg, approx. 10 12GC / kg, approx. 10 12 GC / kg, or approximately 10 14 In some embodiments, the subject is administered a high titer (e.g., >10 12 Genome copies GC / kg of rAAV are administered by injection into the CSF space or by intraparenchymal injection. A composition described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) can be administered to a subject one or more times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, or more). In some embodiments, the composition is administered to a subject continuously (e.g., chronically), e.g., via an infusion pump.
[0053] In some embodiments, a composition described herein (e.g., a composition comprising an isolated nucleic acid or vector or rAAV) can be administered to a subject in combination with another suitable therapeutic agent (e.g., a therapeutic agent for treating AD). Non-limiting examples of other suitable therapeutic agents for treating AD include amyloid-β antibodies (e.g., aducanumab, bapineuzumab, and solanezumab), donepezil, galantamine, rivastigmine, memantine, suvorexant, etc.
[0054] example Example 1: Protective role of APOE3 Christchurch homozygotes in autosomal dominant Alzheimer's disease (ADAD) The presenilin 1 (PSEN1) E280A mutation causes autosomal dominant Alzheimer's disease (ADAD). Although there is some variability in the age of clinical onset and disease course, patients who are carriers of the PSEN1 E280A mutation develop mild cognitive impairment (MCI) and dementia at median ages of 44 years (95% CI, 43-45) and 49 years (95% CI, 49-50), respectively. It was discovered that a subject with the PSEN1 E280A mutation did not develop MCI until her 70s, approximately 30 years after the typical age of onset. The subject's memory deficits were limited to recent events, and her neurological examination was normal. Whole-genome sequencing confirmed her PSEN1 E280A mutation and revealed two copies of the rare Christchurch (APOEch) mutation in APOE3 (an arginine to serine substitution at amino acid 136, corresponding to codon 154). It was confirmed that the PSEN1 E280A mutation was the primary risk factor, and APOE3ch homozygosity was most likely a genetic modifier for this subject. In a subsequent study, subjects with one copy of the APOE3ch mutation along with the PSEN1 E280A mutation were not protected from developing MCI at a mean age of 45 years. This suggests that APOE3ch homozygosity is necessary to delay the clinical onset of ADAD (see, for example, Arboleda-Velasquez et al., Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report, NATURE MEDICINE, VOL 25, NOVEMBER 2019, pp. 1680-1683).
[0055] APOE, the major susceptibility gene for late-onset Alzheimer's disease, has three common alleles (APOE2, APOE3, and APOE4). APOE3 was previously thought to be neutral with respect to Alzheimer's disease risk. APOE2 is associated with a lower risk of Alzheimer's disease and dementia onset at an older age, and each additional copy of APOE4 is associated with a higher risk and earlier onset.
[0056] Interestingly, the APOE3ch homozygous subject exhibited a much higher amyloid-β plaque burden than PSEN1 E280A carriers who were not APOE3ch homozygous. Despite the high amyloid-β plaque burden, the size and spatial extent of her PHF tau burden and neurodegeneration were relatively limited. This subject's tau burden was restricted to the medial temporal and occipital regions, with other regions characteristically affected in the clinical stages of Alzheimer's disease relatively spared. Furthermore, this subject's cerebral metabolic rate for glucose was preserved in areas known to be preferentially affected by Alzheimer's disease. Magnetic resonance imaging showed that this subject's brain atrophy was comparable to that of other PSEN1 E280A carriers who developed MCI in their 40s. The subject also had low plasma neurofilament light chain (NfL), a marker for familial Alzheimer's disease. These findings suggested that APOE3ch homozygotes induced a protective role by limiting tau pathology and neurodegeneration despite high amyloid-β plaque burden.
[0057] It was later confirmed that Aβ42 aggregation was reduced in the presence of APOE3ch protein compared with that in wild-type APOE3 protein. The Aβ42 aggregation levels in the presence of APOE3ch and APOE2 were similar. These results suggest that APOE3ch has a low ability to trigger Aβ42 aggregation. The R136S mutation is located in a region of APOE known to play a role in binding to the lipoprotein receptor (LDLR) and heparan sulfate proteoglycans (HSPGs). Previous reports have shown that, compared with APOE3, APOE2 and APOE3ch are associated with a 98% and 60% reduction in LDLR binding, respectively. APOE binding to HSPGs has been suggested to be necessary for HSPGs to promote amyloid-β aggregation and neuronal uptake of extracellular tau. Compared with other APOE isoforms, APOE3ch exhibited the lowest heparin-binding capacity, and antibody blocking of APOE-HSPG interactions was observed to recapitulate the protective effect of APOE3ch.
[0058] The present disclosure is based, at least in part, on the discovery of a protective role for APOE3ch in subjects with the PSEN1 E280A mutation. Gene therapy delivery of APOE3ch to PSEN1 E280A carriers (e.g., PSEN1 E280A carriers who are not APOE3ch homozygotes) may confer benefits such as delaying the onset of MIC and reducing tau pathology. This example describes an isolated nucleic acid (e.g., an rAAV vector and a vector such as an rAAV containing an isolated nucleic acid) containing an expression construct encoding an APOE Christchurch protein for overexpression of the APOE Christchurch protein. The APOE Christchurch protein can be a recombinant APOE2 Christchurch protein (APOE2ch) or a recombinant APOE3 Christchurch protein (APOE3ch). The sequence encoding APOE2ch and / or APOE3ch is codon-optimized to be sufficiently different from the endogenous APOE2 sequence in cells so that it is not recognized by shRNA targeting wild-type APOE, regardless of isoform.
[0059] The isolated nucleic acid may further comprise a coding sequence for an inhibitory nucleic acid targeting one or more APOE gene isoforms (e.g., APOE4, and / or APOE3, and / or APOE2). In some embodiments, the construct described in this example is useful for treating a subject having or suspected of having Alzheimer's disease (AD) (e.g., autosomal dominant Alzheimer's disease) who is a carrier of the PSEN1 E280A mutation. In some embodiments, the subject has an APOE3 Christchurch mutation (e.g., APOE3 R136S + / + ) is not homozygous. Isolated nucleic acids encoding shRNAs are used to knock down the expression of APOE4 and / or APOE2 isoforms, particularly both, in vitro and in vivo. In some embodiments, the shRNAs are non-allele specific (e.g., they are also capable of knocking down the expression of other APOE isoforms, e.g., E2, E3, or E4).
[0060] shRNA and transgene can be operably linked to the same promoter or different promoters.shRNA is expressed under different promoters, typically under Pol III promoter (for example, H1 promoter) or Pol II promoter (for example, CBA, T7, etc.).Generally, shRNA is operably linked to the Pol II promoter that is located in the intron sequence upstream of the open reading frame that contains codon-optimized APOE2ch and / or APOE3ch transgene.
[0061] Recombinant adeno-associated viruses (rAAVs) containing the isolated nucleic acids are generated using cells such as HEK293 cells for triple-plasmid transfection. ITR sequences typically flank expression constructs containing one or more of the following: at least one promoter / enhancer element, a 3' polyA signal, and a post-translational signal such as a WPRE element. Multiple gene products, such as APOE2ch and / or APOE3ch proteins and one or more inhibitory nucleic acids (e.g., inhibitory nucleic acids targeting the APOE4 and / or APOE2 isoforms of APOE), are simultaneously expressed. The presence of a short, efficiently spliced intron sequence upstream of the expressed gene can improve expression levels. shRNAs and other regulatory RNAs can potentially be included within these sequences.
[0062] Example 2: APOE4 + / + Cell-based assay for viral transduction of cells Cells, such as fibroblasts, monocytes, or human embryonic stem cells (hESCs) from ADAD patients, or patient-derived induced pluripotent stem cells (iPSCs), accumulate proteinaceous plaques containing amyloid-β protein and tangles containing twisted strands of the protein tau.
[0063] Using these cell models, ADAD-associated neurodegenerative features are quantified in terms of the accumulation of protein aggregates, such as plaques and tangles, using, for example, α-amyloid-β or α-phosphorylated tau antibodies, followed by imaging using fluorescence microscopy. ADAD-associated neurodegenerative features are also imaged by ICC of protein markers, such as amyloid-β, phosphorylated tau, PSEN1 E280A, APOE3, APOE3ch, or APOE4. Western blotting, ELISA, and / or qPCR are used to quantify APOE3ch expression levels in these cells.
[0064] Therapeutic endpoints (e.g., reduction of ADAD-related pathology) will be measured in the context of rAAV transduction expression, confirming and quantifying activity and function. Amyloid-β and phosphorylated tau levels will also be quantified using Western blotting, ELISA, and / or qPCR.
[0065] Example 3: Clinical trial of ADAD patients This example describes a clinical trial to assess the safety and efficacy of rAAV described by the present disclosure in patients with ADAD (e.g., PSEN1 E280A carriers, not APOE3ch homozygotes). Clinical trials of the disclosed rAAV for the treatment of ADAD will be conducted using a study design similar to that described in Grabowski et al. (1995) Ann. Intern. Med. 122(1):33-39. The rAAV will be delivered into the CSF, intraparenchyma, to the hippocampus, or to another brain region, or peripherally. Endpoints measured are amyloid-beta plaque levels, tau tangles, motor and cognitive endpoints, and APOE3ch, APOE4, and APOE2 protein levels.
[0066] Example 4: Clinical trial in ADAD patients in combination with amyloid-β antibodies This example describes a clinical trial to assess the safety and efficacy of rAAV described by the present disclosure utilized in combination with amyloid-β antibodies (e.g., bapineuzumab and solanezumab) in patients with ADAD (e.g., non-APOE3ch homozygotes, PSEN1 E280A carriers). Clinical trials of the disclosed rAAV in combination with anti-amyloid-β antibodies for the treatment of ADAD will be conducted using a study design similar to that described in Grabowski et al. (1995) Ann. Intern. Med. 122(1):33-39. The rAAV will be delivered to the CSF, intraparenchyma, the hippocampus, or another brain region, or peripherally.
[0067] In some embodiments, the rAAV of the present disclosure synergizes with anti-amyloid-β antibody to reduce the likelihood that AD patients will develop amyloid-associated imaging abnormalities (ARIA), which is highly correlated with APOE genotype.ARIA is a series of abnormalities observed in AD patients, specifically related to amyloid-modifying therapy with human monoclonal antibodies.There are two types of ARIA: ARIA-E, which refers to cerebral edema, and ARIA-H, which refers to cerebral microbleeds.
[0068] Endpoints evaluated include pre- and post-treatment brain imaging to determine whether ARIA occurs, and whether the rAAV disclosed herein reduces the likelihood of ARIA, amyloid-beta plaque levels, tau tangles, motor and cognitive endpoints, and APOE3ch, APOE4, and APOE2 protein levels.
[0069] Example 5: APOE3ch + / + , APOE3ch + / - , and APOE3ch - / - Clinical trial in ADAD patients with the PSEN1 E280A mutation This example shows APOE3ch + / - or APOE3ch - / - APOE3ch compared with patients with + / + Clinical trials are described to assess the efficacy of the rAAV described by this disclosure in ameliorating the increased risk of other conditions, including stroke, coronary artery disease, atherosclerosis, poor recovery from head trauma, and cognitive recovery from bypass surgery, in patients with the PSEN1 E280A mutation but not those with the PSEN1 E280A mutation.
[0070] AD treatment and APOE3ch + / - , or APO3ch - / -Clinical trials of the disclosed rAAV for ameliorating the increased risk of other conditions associated with patients with the PSEN1 E280A mutation will be conducted using a study design similar to that described in Grabowski et al. (1995) Ann. Intern. Med. 122(1):33-39. The rAAV will be delivered to the CSF, intraparenchyma, the hippocampus, or another brain region, or peripherally. Endpoints assessed before and after treatment with the rAAV of the present disclosure include blood pressure, blood cholesterol and blood glucose levels, motor and cognitive endpoints, MRI, PET, and ultrasound imaging of the coronary arteries, recovery from cognitive trauma, and recovery from surgery with bypass devices.
[0071] Example 6: Prevention of ADAD or treatment of ADAD in patient carriers of the PSEN1 E280A mutation This example describes a clinical trial to assess the efficacy of the rAAV described by the present disclosure in reducing the risk of developing AD in subjects with the PSEN1 E280A mutation and in treating AD in patients with the PSEN1 E280A mutation. + / - or APOE3ch - / - It can be either of the following.
[0072] Clinical trials of the disclosed rAAV for the prevention or treatment of AD in carriers of PSEN1 E280A will be conducted using a study design similar to that described in Grabowski et al. (1995) Ann. Intern. Med. 122(1):33-39. The rAAV will be delivered to the CSF, intraparenchyma, the hippocampus, or another brain region, or peripherally. Endpoints assessed before and after treatment with the rAAV of the present disclosure are APOE3ch, APOE4 and APOE2 levels in CSF and blood, as well as cognitive and motor endpoints.
[0073] Example 7: In vitro validation of shRNAs for endogenous APOE silencing and APOE Christchurch protein overexpression Multiple plasmids containing unique APOE shRNAs and codon-optimized coding sequences for APOE Christchurch proteins (e.g., APOE3ch and / or APOE2ch) were evaluated in an in vitro transfection screen to assess the degree of APOE (e.g., APOE4 and / or APOE2) knockdown and heterologous expression of APOE Christchurch proteins (e.g., APOE3ch and / or APOE2ch). The plasmids were specifically designed to selectively knock down the endogenous APOE gene without affecting the vector-encoded APOE Christchurch proteins (e.g., APOE3ch and / or APOE2ch). Multiple plasmids demonstrate reduced endogenous APOE and expression of the codon-optimized APOE Christchurch proteins (e.g., APOE3ch and / or APOE2ch) via qRT-PCR. The shRNA candidates exhibit significant reduction of endogenous APOE without affecting expression of APOE Christchurch proteins (eg, APOE3ch and / or APOE2ch).
[0074] Example 8: In vivo validation of shRNAs for endogenous APOE silencing and APOE Christchurch protein (e.g., APOE3ch and / or APOE2ch) overexpression shRNA candidates that demonstrate significant reduction of endogenous APOE without affecting the codon-optimized APOE Christchurch protein coding sequence (e.g., APOE3ch and / or APOE2ch coding sequences) are selected for further in vivo studies. An APOE4 knock-in (KI) mouse model is used to evaluate the in vivo efficacy of candidate shRNAs against APOE4. In APOE4 KI mice, both mouse Apoe alleles are replaced with human APOE-ε4. Mice (n=5) receive a vector carrying a candidate shRNA against APOE4 via intracerebroventricular injection (ICV), and the biodistribution of human APOE4 mRNA is analyzed 60 days after injection.
[0075] equivalent Having thus described several aspects of at least one embodiment of this invention, it should be understood that various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be part of this disclosure, and are intended to be within the spirit and scope of the invention. Accordingly, the foregoing description and drawings are by way of example only.
[0076] While several embodiments of the present invention have been described and illustrated herein, those skilled in the art will readily envision various other means and / or structures for performing the functions and / or obtaining the results and / or one or more advantages described herein, and each such variation and / or modification is deemed to be within the scope of the present invention. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application(s) for which the teachings of the present invention are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Accordingly, the foregoing embodiments are presented by way of example only, and it should be understood that, within the scope of the appended claims and their equivalents, the invention may be practiced otherwise than as specifically described and claimed. The present invention is directed to each individual feature, system, article, material, and / or method described herein. Furthermore, any combination of two or more such features, systems, articles, materials, and / or methods is included within the scope of the present invention, if such features, systems, articles, materials, and / or methods are not mutually inconsistent.
[0077] The indefinite articles "a" and "an," as used in the specification and claims, unless clearly indicated to the contrary, should be understood to mean "at least one." The term "and / or," as used in the specification and claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Unless clearly indicated to the contrary, optional other elements may be present other than the elements specifically identified in the "and / or" clause, whether or not related to the elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B," when used in combination with open-ended language such as "comprising," can, in one embodiment, refer to A without B (optionally including elements other than B); in another embodiment, it can refer to B without A (optionally including elements other than A); in yet another embodiment, it can refer to both A and B (optionally including other elements); and so forth.
[0078] As used in this specification and the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one of the number or list of elements, and also including more than one, and optionally including additional unlisted items. Unless clearly indicated in terms to the contrary, such as "only one of" or "exactly one," or when used in the claims, "consisting of" refers to the inclusion of exactly one of the number or list of elements. In general, the term "or" as used herein, when preceded by terms of exclusivity, such as "either," "one of," or "only one," or "exactly one," should be interpreted as referring to exclusive alternatives (i.e., one or the other, but not both). When used in the claims, "consisting essentially of" shall have its ordinary meaning as used in the field of patent law.
[0079] As used in this specification and claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more elements of the list of elements; but not necessarily including at least one of every element specifically listed in the list of elements, nor excluding any combination of elements in the list of elements. This definition allows for the optional presence of elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, whether related to the specifically identified elements or not. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") means, in one embodiment, at least one, optionally more than one, A, and no B (and optionally including elements other than B); in another embodiment, at least one, optionally more than one, B, and no A (optionally including elements other than A); in yet another embodiment, at least one, optionally more than one, A, and at least one, optionally more than one, B (and optionally including other elements); and so forth.
[0080] In the claims and the above specification, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," etc., are to be understood as open-ended, i.e., to mean inclusion without limitation. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in Section 2111.03 of the U.S. Patent Office Manual of Patent Examining Procedure. The use of ordinal terms such as "first," "second," "third," etc. in a claim to modify a claim element does not, in itself, indicate the priority, precedence, or order of one claim element relative to another, or the temporal order in which the actions of a method are performed, but is used solely as a label to distinguish a given claim element having a particular name from another element having the same name (but differing only in ordinal terms) to distinguish the claim elements. It should also be understood that, unless expressly stated to the contrary, in any method claimed herein that includes one or more steps or actions, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are presented.
[0081] array In some embodiments, an expression cassette encoding one or more gene products (e.g., a first, second, and / or third gene product) comprises or consists of a sequence set forth in any one of SEQ ID NOs: 1-24. In some embodiments, a gene product is encoded by a portion (e.g., a fragment) of a sequence set forth in any one of SEQ ID NOs: 1-24. One skilled in the art will understand that a nucleic acid sequence encoding an inhibitory nucleic acid can describe a sequence in which all "T"s are replaced by "U", and vice versa.
[0082] Human APOE4 nucleic acid sequence (SEQ ID NO: 1) ATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAGGTCACCCAGGAACTGAGGGCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGCGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA
[0083] >ヒトAPOE2 nucleic acid sequence(sequential number 2) ATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGGAGCTGCTCGCCAGGTCACCCAGGAACTGAGG CGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTGACCCCGGTGGCGGAGGACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCGCCTGGTGCAGTACCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGTGCGCCTCGCCTCCCACCTG CGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGTGCCTGGCAGTGTACCAGGCGGGCCGCGAGGGCGCCGAGCGCGGCCTCACGCCATCCGCGAGCGCCTGGGGCCCCTGGTGGAAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCTGGCCGGCCAGCCGCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGA TGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGAGGTGCGCGCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCAGCGACAATCACTGA
[0084] Human ApoE2 amino acid sequence (SEQ ID NO: 3) MKVLWAALLVTLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASH LRKLRKRLLRDADDLQKCLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
[0085] Human APOE3 nucleic acid sequence (SEQ ID NO: 4)
[0086] Human ApoE3 amino acid sequence (SEQ ID NO: 5) MKVLWAALLVTLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASH LRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
[0087] Human ApoE3 Christchurch mutant amino acid sequence (SEQ ID NO: 6) MKVLWAALLVTLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVSLASH LRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
[0088] Human ApoE3 Christchurch mutant nucleic acid sequence (SEQ ID NO: 7) ATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAGGTCACCCAGGAACTGAGGGCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGAGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA
[0089] Human ApoE2 Christchurch mutant amino acid sequence (SEQ ID NO: 8) MKVLWAALLVTLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVSLASH LRKLRKRLLRDADDLQKCLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
[0090] Human ApoE2 Christchurch mutant nucleic acid sequence (SEQ ID NO: 9) ATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAGGTCACCCAGGAACTGAGGGCGCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGAGCCTCGCCTCCCACCTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGTGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCGCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA
[0091] Codon-optimized nucleic acid sequence of human ApoE3 Christchurch mutant (SEQ ID NO: 10) ATGAAGGTGCTGTGGGCCGCCCTGCTGGTGACCTTCCTGGCCGGCTGCCAGGCCAAaGTcGAaCAGGCCGTcGAGACCGAGCCCGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAGCTGGCCCTGGGCCGCTTCTGGGACTACCTGCGCTGGGTGCAGACCCTGAGCGAGCAGGTGCAGGAGGAGCTGCTGAGCAGCCAGGTGACCCAGGAGCTGCGCGCCCTGATGGACGAGACCATGAAaGAaCTcAAaGCtTAtAAGAGCGAGCTGGAGGAGCAGCTGACCCCCGTGGCCGAGGAGACCCGCGCCCGCCTGAGCAAGGAGCTGCAGGCCGCCCAGGCCCGCCTGGGCGCCGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTGGGCCAGAGCACCGAGGAGCTGCGCGTGAGCCTGGCCAGCCACCTGCGCAAGCTGCGCAAGCGCCTGCTGCGCGACGCCGACGACCTGCAGAAGCGCCTGGCCGTGTACCAGGCCGGCGCCCGCGAGGGCGCCGAGCGCGGCCTGAGCGCCATCCGCGAGCGCCTGGGCCCCCTGGTGGAGCAGGGCCGCGTGCGCGCCGCCACCGTGGGCAGCCTGGCCGGCCAGCCCCTGCAGGAGCGCGCCCAGGCCTGGGGCGAGCGCCTGCGCGCCCGCATGGAGGAGATGGGCAGCCGCACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCCGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATCCGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTGAAGAGCTGGTTCGAGCCCCTGGTGGAGGACATGCAGCGCCAGTGGGCCGGCCTGGTGGAGAAGGTGCAGGCCGCCGTGGGCACCAGCGCCGCCCCCGTGCCCAGCGACAACCACTAA
[0092] Codon-optimized nucleic acid sequence of human ApoE2 Christchurch mutant (SEQ ID NO: 11) ATGAAGGTGCTGTGGGCCGCCCTGCTGGTGACCTTCCTGGCCGGCTGCCAGGCCAAaGTcGAaCAGGCCGTcGAGACCGAGCCCGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGCGCTGGGAGCTGGCCCTGGGCCGCTTCTGGGACTACCTGCGCTGGGTGCAGACCCTGAGCGAGCAGGTGCAGGAGGAGCTGCTGAGCAGCCAGGTGACCCAGGAGCTGCGCGCCCTGATGGACGAGACCATGAAaGAaCTcAAaGCtTAtAAGAGCGAGCTGGAGGAGCAGCTGACCCCCGTGGCCGAGGAGACCCGCGCCCGCCTGAGCAAGGAGCTGCAGGCCGCCCAGGCCCGCCTGGGCGCCGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTGGGCCAGAGCACCGAGGAGCTGCGCGTGAGCCTGGCCAGCCACCTGCGCAAGCTGCGCAAGCGCCTGCTGCGCGACGCCGACGACCTGCAGAAGTGCCTGGCCGTGTACCAGGCCGGCGCCCGCGAGGGCGCCGAGCGCGGCCTGAGCGCCATCCGCGAGCGCCTGGGCCCCCTGGTGGAGCAGGGCCGCGTGCGCGCCGCCACCGTGGGCAGCCTGGCCGGCCAGCCCCTGCAGGAGCGCGCCCAGGCCTGGGGCGAGCGCCTGCGCGCCCGCATGGAGGAGATGGGCAGCCGCACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCCGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATCCGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTGAAGAGCTGGTTCGAGCCCCTGGTGGAGGACATGCAGCGCCAGTGGGCCGGCCTGGTGGAGAAGGTGCAGGCCGCCGTGGGCACCAGCGCCGCCCCCGTGCCCAGCGACAACCACTAA
[0093] ApoE shRNA 1 nucleic acid sequence (SEQ ID NO: 12) TTGTAGGCCTTCAACTCCTTC ApoE shRNA 1 nucleic acid sequence (SEQ ID NO: 13) GAAGGAGTTGAAGGCCTACAA ApoE shRNA 1 with loop (SEQ ID NO: 14) TTGTAGGCCTTCAACTCCTTCCATCTGTGGCTTCACTGAAGGAGTTGAAGGCCTACAA
[0094] >ApoE amiRNA 1 (SEQ ID NO: 15) ttgtcatcctcccacggtggccatttgttccatgtgagtgctagtaacaggccttgtgtcctTTGTAGGCCTTCAACTCCTTCCATCTGTGGCTTCACTGAAGGAGTTGAAGGCCTACAAgacaacagcatacagccttcagcaagcctcca ApoE shRNA 2 nucleic acid sequence (SEQ ID NO: 16) ctccaccgcttgctccacctt ApoE shRNA 2 nucleic acid sequence (SEQ ID NO: 17) aaggtggagcaagcggtggag
[0095] ApoE shRNA 2 with loop (SEQ ID NO: 18) ctccaccgcttgctccaccttAGTGAAGCCACAGATGaaggtggagcaagcggtggag >ApoE amiRNA 2 (SEQ ID NO: 19) tggaggcttgctgaaggctgtatgctgttgtcctccaccgcttgctccaccttAGTGAAGCCACAGATGaaggtggagcaagcggtggagaggacacaaggcctgttactagcactcacatggaacaaatggccaccgtgggaggatgacaa ApoE shRNA 3 nucleic acid sequence (SEQ ID NO: 20) tttgtaggccttcaactcc ApoE shRNA 3 nucleic acid sequence (SEQ ID NO: 21) ggagttgaaggcctacaaa
[0096] >ApoE shRNA 3 with loop (SEQ ID NO: 22) tttgtaggccttcaactccAGTGAAGCCACAGATGggagttgaaggcctacaaa >ApoE amiRNA 3 (SEQ ID NO: 23) tggaggcttgctgaaggctgtatgctgttgtctttgtaggccttcaactccAGTGAAGCCACAGATGggagttgaaggcctacaaaaggacacaaggcctgttactagcactcacatggaacaaatggccaccgtgggaggatgacaa Wild-type AAV2 ITR nucleic acid sequence (SEQ ID NO: 24) AGGAACCCCTAGTGATGGAGTTGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGGGAGTGGCCAA
Claims
1. An isolated nucleic acid, comprising an expression construct comprising a nucleic acid encoding an APOE Christchurch protein.
2. 2. The isolated nucleic acid of claim 1, wherein the APOE Christchurch protein is an APOE3 Christchurch protein.
3. The isolated nucleic acid of claim 2, wherein the APOE3 Christchurch protein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:
6.
4. 4. The isolated nucleic acid of claim 2 or 3, wherein the nucleic acid sequence encoding the APOE3 Christchurch protein comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:
7.
5. 2. The isolated nucleic acid of claim 1, wherein the APOE Christchurch protein is an APOE2 Christchurch protein.
6. The isolated nucleic acid of claim 5, wherein the APOE2 Christchurch protein comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
8.
7. 7. The isolated nucleic acid of claim 5 or 6, wherein the nucleic acid sequence encoding the APOE2 Christchurch protein comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO:
9.
8. 8. The isolated nucleic acid of any one of claims 1 to 7, wherein the expression construct further comprises a first promoter operably linked to the nucleic acid sequence encoding the APOE Christchurch protein.
9. The isolated nucleic acid of claim 8, wherein the expression construct further comprises a second promoter.
10. 10. The isolated nucleic acid of claim 8 or 9, wherein the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits expression or activity of the APOE gene.
11. The isolated nucleic acid of any one of claims 8 to 10, wherein the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits APOE4 expression or activity.
12. The isolated nucleic acid of any one of claims 8 to 11, wherein the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits APOE2 expression or activity.
13. The isolated nucleic acid of any one of claims 8 to 12, wherein the expression construct further comprises a nucleic acid sequence encoding an inhibitory nucleic acid that inhibits the expression or activity of APOE4 and APOE2.
14. The isolated nucleic acid of any one of claims 10 to 13, wherein the inhibitory nucleic acid is a double-stranded ribonucleic acid (dsRNA), a small interfering RNA (siRNA), a small hairpin RNA (shRNA), a microRNA (miRNA) or an artificial miRNA (amiRNA).
15. 14. The isolated nucleic acid according to any one of claims 10 to 13, wherein the inhibitory nucleic acid or a part thereof is encoded by a sequence represented by any one of SEQ ID NOs: 12 to 23.
16. 16. The isolated nucleic acid of claim 14 or 15, wherein the inhibitory nucleic acid is an shRNA comprising a region of complementarity encoded by the sequence represented by SEQ ID NO: 13, 17, or 21.
17. The isolated nucleic acid of any one of claims 14 to 16, wherein the inhibitory nucleic acid is an shRNA encoded by a sequence represented by SEQ ID NO: 14, 18, or 22.
18. 16. The isolated nucleic acid of claim 14 or 15, wherein the inhibitory nucleic acid is an amiRNA encoded by a sequence represented by SEQ ID NO: 15, 19, or 23.
19. 19. The isolated nucleic acid of any one of claims 8 to 18, wherein the first promoter is operably linked to a nucleic acid sequence encoding an inhibitory nucleic acid.
20. 20. The isolated nucleic acid of any one of claims 9 to 19, wherein a second promoter is operably linked to the nucleic acid sequence encoding the inhibitory nucleic acid.
21. 21. The isolated nucleic acid of any one of claims 9 to 20, wherein the first promoter and / or the second promoter are independently a chicken beta actin (CBA) promoter, a cytomegalovirus early enhancer / CBA promoter (CAG) promoter, a CD68 promoter, or a JeT promoter.
22. 22. The isolated nucleic acid of any one of claims 1 to 21, wherein the expression construct is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).
23. 23. The isolated nucleic acid of claim 22, wherein the ITR is an AAV2 ITR.
24. 24. The isolated nucleic acid of any one of claims 1 to 23, wherein the nucleic acid sequence encoding the APOE Christchurch protein comprises a sequence represented by any one of SEQ ID NOs: 1 to 3, 10 and 11.
25. A vector comprising the isolated nucleic acid of any one of claims 1 to 24.
26. 26. The vector of claim 25 which is a plasmid.
27. 26. The vector of claim 25, wherein the vector is a viral vector, optionally wherein the viral vector is a recombinant AAV (rAAV) vector or a baculovirus vector.
28. below: (i) AAV capsid proteins; and (ii) An isolated nucleic acid according to any one of claims 1 to 24, or a vector according to claim 27. A recombinant adeno-associated virus (rAAV).
29. The rAAV of claim 28, wherein the AAV capsid protein is capable of crossing the blood-brain barrier, and optionally, the capsid protein is an AAV9 capsid protein or an AAVrh.10 capsid protein.
30. The rAAV of claim 28 or 29, which transduces neuronal and non-neuronal cells of the central nervous system (CNS).
31. A host cell comprising an isolated nucleic acid according to any one of claims 1 to 24, a vector according to any one of claims 25 to 27, or an rAAV according to any one of claims 28 to 30.
32. A composition comprising an isolated nucleic acid according to any one of claims 1 to 24, a vector according to any one of claims 25 to 27, or an rAAV according to any one of claims 28 to 30.
33. 33. The composition of claim 32, which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.
34. 31. A pharmaceutical composition for treating a subject having or suspected of having Alzheimer's disease, comprising an isolated nucleic acid according to any one of claims 1 to 24, a vector according to any one of claims 25 to 27, or an rAAV according to any one of claims 28 to 30.
35. 35. The pharmaceutical composition of claim 34, wherein the composition is administered to a subject via direct injection into the central nervous system (CNS).
36. 36. The pharmaceutical composition of claim 35, wherein the direct injection is an intracerebral injection, an intraparenchymal injection, an intrathecal injection, or any combination thereof.
37. 36. The pharmaceutical composition of claim 35, wherein the direct injection into the CNS of the subject is convection-enhanced delivery (CED).
38. 35. The pharmaceutical composition of claim 34, which is administered to a subject via peripheral injection.
39. The pharmaceutical composition of claim 38, wherein the peripheral injection is an intravenous injection.
40. The pharmaceutical composition according to any one of claims 34 to 39, wherein the Alzheimer's disease is autosomal dominant Alzheimer's disease (ADAD).
41. The pharmaceutical composition of any one of claims 34 to 40, wherein the subject has at least one mutation in the PSEN1 gene.
42. 42. The pharmaceutical composition of claim 41, wherein the mutation in the PSEN1 gene causes the E280A mutation in the presenilin 1 protein.
43. The pharmaceutical composition according to any one of claims 34 to 42, wherein the subject is homozygous for the PSEN1 E280A mutation.
44. 44. The pharmaceutical composition of any one of claims 34 to 43, wherein the subject is not homozygous for the APOE3 Christchurch mutation, wherein the APOE3 Christchurch mutation causes a R136S mutation in the APOE3 protein.
45. The pharmaceutical composition according to any one of claims 34 to 44, wherein administration of the pharmaceutical composition to a subject results in a delayed onset of mild cognitive impairment (MIC) compared to a non-administered subject.
